The global blood screening market was valued at USD 2.31 billion in 2018 and is expected to reach USD 6.63 billion by 2032, growing at a compound annual rate of 7.9% over the forecast period. In 2018, North America held the largest share of the market at 41.86%.
The global blood screening market has experienced steady growth and is projected to expand significantly over the coming years. Rising demand for safe blood transfusions, increasing prevalence of infectious diseases, and technological advancements in screening methods are key factors driving this growth. North America currently leads the market due to strong healthcare infrastructure and early adoption of advanced technologies, while other regions are rapidly emerging as important contributors.
Learn more here:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation
- By Product
- Reagents and Kits: Widely used for screening of infectious markers and dominating due to their recurring use.
- Instruments: Includes automated analyzers and devices for nucleic acid testing, immunoassays, and rapid testing platforms.
- Software and Services: Growing in importance as data management and automation become critical in blood banks and laboratories.
- By Technology
- Nucleic Acid Testing (NAT): Highly sensitive technology increasingly adopted to detect viral infections at early stages.
- Enzyme-Linked Immunosorbent Assay (ELISA): Extensively used and evolving with chemiluminescent and advanced formats.
- Rapid Tests: Used for quick screening in resource-limited or emergency settings.
- Western Blotting and Next-Generation Sequencing: Applied for confirmatory and advanced diagnostic purposes.
- By Application
- Infectious Disease Screening: Focused on detection of HIV, hepatitis, syphilis, malaria, and other transfusion-transmissible infections.
- Blood Group Typing: Essential for ensuring compatibility in transfusions and transplantation.
- By End User
- Blood Banks: Major end users performing high volumes of routine screening.